Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||Relugolix||Phase III||Actionable||In a Phase III trial (HERO), Relugolix (TAK-385) demonstrated superior serum testosterone suppression and maintenance of castration compared to Lupron (leuprolide) (96.7%, 601/622 vs 88.8%, 273/308, p<0.0001) in patients with androgen-sensitive advanced prostate cancer (PMID: 32469183; NCT03085095).||32469183|
|Unknown unknown||prostate cancer||not applicable||Relugolix||Phase II||Actionable||In a Phase II trial, Relugolix (TAK-385) resulted in decreased testosterone levels and greatly reduced prostate specific antigen levels after 24 weeks in prostate cancer patients (J Clin Oncol 34, 2016 (suppl 2S; abstr 200)).||detail...|